Accugenomics
Dan has more than 25 years of focused experience within the life science, diagnostic and pharmaceutical industry. Of those, he spent more than 12 years in research working across institutions including The Children’s Hospital of Philadelphia, The University of Pennsylvania, and Wyeth Research (now Pfizer). Following these years in the lab, Dan then spent 15 years focused on consultative workflow-based approaches with his clients, holding commercial roles of increasing responsibility with market-leading organizations including Promega, Roche Diagnostics, and Illumina. In these roles, Dan supported the needs of some of the world’s leading pharmaceutical and CRO organizations by establishing customer centric relationships and consistently demonstrating the highest levels of trust and integrity with global clients. Dan holds a BS in Biology (Rutgers University), and a Master’s Degree in Cell & Molecular Biology (Rutgers University).
This person is not in any offices
Accugenomics
AccuGenomics is a developer of a unique spike-in control technology that dramatically improves the accuracy and performance of clinical sequencing tests for low abundance biomarkers such as circulating tumor DNA (ctDNA) and low titer infectious pathogens such as SARS-CoV-2.